Inhaler options multiply with launch of new salmeterol/fluticasone MDI

Sereflo (salmeterol/fluticasone) is indicated for adults with asthma where the use of a long-acting ß2-agonist and inhaled corticosteroid is appropriate.

Sereflo (salmeterol/fluticasone) provides an additional option for asthma patients needing a combination inhaler.
Sereflo (salmeterol/fluticasone) provides an additional option for asthma patients needing a combination inhaler.

Sereflo is licensed for patients with moderate to severe asthma who are not adequately controlled on a lower strength corticosteroid combination product. It can also be used in patients already adequately controlled on a mid- or high-strength inhaled corticosteroid and a long-acting β2-agonist. 

The metered-dose inhaler is available in two strengths:

  • 25/125 (salmeterol 25 microgram, fluticasone propionate 125 microgram)
  • 25/250 (salmeterol 25 microgram, fluticasone propionate 250 microgram)

Use of a spacer is recommended only for Sereflo 25/250, with which the Volumatic device and the AeroChamber Plus are both compatible. If a spacer is required for use with Sereflo 25/125, prescribers are advised to issue patients with an alternative inhaler. 

The efficacy and safety of salmeterol and fluticasone for the treatment of asthma are well established. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in